ArticleCell reports. Medicine2024
Circulating microbiome DNA as biomarkers for early diagnosis and recurrence of lung cancer.
Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- GDF-15 as a biomarker for diagnosis and prognosis of lung cancer: a meta-analysis.Frontiers in oncology · 2025Pooled it
- A machine-learning informed circulating microbial DNA signature for early diagnosis of esophageal adenocarcinoma.Gut microbes · 2026Article
- Review
- Article
- Multifeature sequencing-based liquid biopsy for cancer diagnosis and monitoring.Genome medicine · 2026Review
- Bacteria mediated tumor therapy recent advances challenges and future perspectives.Discover oncology · 2026Review
- Microbiome-host interactions in different pathomic subtypes of early-stage lung adenocarcinoma.BMC pulmonary medicine · 2026Article
- Microbial Influence on Immune Checkpoint Inhibitor Therapy in Non-Small Cell Carcinoma: The Gut-Lung-Immune Axis.Cancers · 2026Review
- Early detection of gastric cancer: a novel circulating microbiome DNA based liquid biopsy assay.NPJ precision oncology · 2026Article
- The non-bacterial oncobiome: the role of the mycobiome and virome in tumor plasticity.Journal of the Egyptian National Cancer Institute · 2026Review
- Machine Learning-Based Lung Cancer Classification Using Blood-Derived Microbial DNA: A Comparative Analysis of Taxonomic Profiling Strategies.Diagnostics (Basel, Switzerland) · 2026Article
- A lung microbial signature for postoperative recurrence in stage I-II non-small cell lung cancer.Respiratory research · 2026Article
- Circulating extrachromosomal circular DNA as a prognostic biomarker for colorectal cancer.Cell communication and signaling : CCS · 2026Article
- Tissue-Derived Extracellular Vesicles Define Diagnostic Biomarkers for Renal Cell Carcinoma.Journal of extracellular vesicles · 2026Article
- Microflora: a promising potential in the diagnosis and treatment of non-small cell lung cancer.International journal of clinical oncology · 2026Review
- Identification and evaluation of gut microbiome as non-invasive biomarkers for early lung adenocarcinoma from a multi-center study.Frontiers in cellular and infection microbiology · 2026Article
- Intralesional microbial community signatures across histopathologic categories of tongue lesions.Frontiers in microbiology · 2026Article
- Assessment of 16S rRNA sequencing for analysis of circulating microbial DNA in colorectal cancer patients-proof of concept and early changes during experimental chemoimmunotherapy.Frontiers in microbiology · 2026Article
- A prognostic nomogram for colorectal cancer: integrating blood microbiome and clinical factors.Journal of gastrointestinal oncology · 2025Article
- Microbiome analysis of 940 lung cancers in never-smokers reveals lack of clinically relevant associations.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer mortality is exacerbated by late-stage diagnosis. Emerging evidence indicates the potential clinical significance of distinct microbial signatures as diagnostic and prognostic biomarkers across various cancers. However, circulating microbiome DNA (cmDNA) profiles are underexplored in lung cancer (LC). Here, whole-genome sequencing is performed on plasma of LC patients and healthy controls (HCs). Differentially enriched microbial species are identified between LC and HC. A diagnostic model is developed, which has a high sensitivity of 87.7% and achieves an AUC of 93.2% in the independent validation dataset. Crucially, this model demonstrates the capability to detect early-stage LC, achieving a sensitivity of 86.5% for stage I and 87.1% for tumors <1 cm. In addition, we construct a cmDNA model for recurrence, which precisely predicts LC recurrence after surgery. Overall, this study highlights the significant alterations of cmDNA profiles in LC, indicating its potential as biomarkers for early diagnosis and recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.